
|Podcasts|April 26, 2018
Significant Improvement Found in Clinical Trial for Dravet Syndrome
Author(s)Andrew N. Wilner, MD
An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.
Advertisement
Fenfluramine proved successful in decreasing seizure frequency in a Phase 3 study of Dravet syndrome, a rare pediatric condition known for its treatment resistance.
In this podcast, Dr. Wilner interviews Arnold Gammaitoni, PharmD, about this potentially game-changing new epilepsy drug.
If these results can be duplicated, it raises the possibility of a new, effective treatment for seizures in children with Dravet syndrome.
RELATED CONTENT:
More podcasts
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What Clinicians Need to Know About Emerging Stem Cell Therapies for Parkinson Disease
2
Atogepant Gains European Approval as Acute and Preventive Migraine Therapy
3
Inside the Development of ISSCR’s New Parkinson Disease Stem Cell Program
4
Improving Access to Cognitive Screening in Multiple Sclerosis Care: Elizabeth S. Gromisch, PhD, MSCS
5













